[et_pb_section fb_built="1" specialty="on" _builder_version="4.9.3" _module_preset="default" custom_padding="0px|0px|0px|||"][et_pb_column type="3_4" specialty_columns="3" _builder_version="3.25" custom_padding="|||" custom_padding__hover="|||"][et_pb_row_inner _builder_version="4.9.3" _module_preset="default" custom_margin="|||-44px|false|false" custom_margin_tablet="|||0px|false|false" custom_margin_phone="" custom_margin_last_edited="on|tablet" custom_padding="28px|||||"][et_pb_column_inner saved_specialty_column_type="3_4" _builder_version="4.9.3" _module_preset="default"][et_pb_text _builder_version="4.9.3" _module_preset="default" hover_enabled="0" sticky_enabled="0"]
-
Dayvigo Sleeping medication
QUESTION
Discuss indications for use, FDA approval, major interactions, side effects, contraindications, and so on
Make bullets o slides and notes in speakers notes
[/et_pb_text][et_pb_text _builder_version="4.9.3" _module_preset="default" width_tablet="" width_phone="100%" width_last_edited="on|phone" max_width="100%"]
| Subject |
Nursing |
Pages |
3 |
Style |
APA |
[/et_pb_text][/et_pb_column_inner][/et_pb_row_inner][et_pb_row_inner module_class="the_answer" _builder_version="4.9.3" _module_preset="default" custom_margin="|||-44px|false|false" custom_margin_tablet="|||0px|false|false" custom_margin_phone="" custom_margin_last_edited="on|tablet"][et_pb_column_inner saved_specialty_column_type="3_4" _builder_version="4.9.3" _module_preset="default"][et_pb_text _builder_version="4.9.3" _module_preset="default" width="100%" custom_margin="||||false|false" custom_margin_tablet="|0px|||false|false" custom_margin_phone="" custom_margin_last_edited="on|desktop"]
Answer
Dayvigo: Sleeping Medication
- This presentation discussed Dayvigo (lemborexant) indications for use, U.S. Food and Drug Administration approval, major interactions, side effects, and contraindications.
Indications for Use
- Dayvigo (lemborexant) is an orexin receptor antagonist whose controlled substance schedule is pending (FDA, 2019).
- Dayvigo is indicated for the treatment of adults with trouble falling or staying asleep (insomnia) (U.S. Food and Drug Administration (FDA), 2020).
- It is found as an oral tablet (5 mg and 10 mg tablets). It is taken not more than once per night; it should be taken straightaway after going to bed (FDA, 2019; 2020).
- Insomnia patients who take the drug tend to fall asleep faster and stay asleep longer compared to patients who receive placebo (FDA, 2020).
- The drug is being investigated for management of irregular sleep-wake rhythm disorder associated with mild to moderate Alzheimer’s disease (Scott, 2020).
FDA Approval
- Dayvigo received its first approval in December 2019 in the United States (Scott, 2020).
- FDA approved Dayvigo for management of insomnia based on primary evidence derived from two clinical trials (Trial 2/NCT02783729 and Trial 1/NCT02952820), which involved a total of 1,692 patients (FDA, 2020).
- The trials were conducted in 164 sites in Canada, United States, Europe, Japan, Mexico, Taiwan, and Korea (FDA, 2020).
- Mechanism of action is by blocking the binding of neuropeptides orexin B and orexin A to OX2R and OXIR, this mechanism is thought to suppress the wake drive (FDA, 2019).
Major Interactions
- Concomitant use with moderate (verapamil and fluconazole) or strong (clarithromycin and itraconazole) CYP3A inhibitors should be avoided (Ardeljan & Hurezeanu, 2020; FDA, 2019).
- CYP3A inhibitors may increase the side effects of Dayvigo.
- The maximum dose of the drug when co-administered with weak CYP3A inhibitors is 5 mg (Ardeljan & Hurezeanu, 2020; FDA, 2019).
- Concomitant use with strong CYP3A inducers (carbamazepine, rifampin, and St. John’s wort) or moderate CYP3A inducers (efavirenz, bosentan, modefinil, and etravirine) should be avoided (Ardeljan & Hurezeanu, 2020; FDA, 2019).
Side Effects
Dayvigo may cause a number of side effects including:
- Drowsiness, which is the most common side effect (FDA, 2020).
- Impaired ability to operate machinery and decreased daytime alertness (FDA, 2020).
- Sleep paralysis (this is temporary inability to talk or walk while waking up or while going to sleep) (FDA, 2020).
- Complex sleep behaviors including sleep-driving and sleep-walking.
- Hallucinations, which occur while waking up or going to sleep (FDA, 2020).
- Suicidal thoughts and worsening depression (FDA, 2020).
- Compromised respiratory function (FDA, 2019).
Contraindications
- Dayvigo is contraindicated in patients with narcolepsy (FDA, 2019).
[/et_pb_text][/et_pb_column_inner][/et_pb_row_inner][et_pb_row_inner _builder_version="4.9.3" _module_preset="default" custom_margin="|||-44px|false|false" custom_margin_tablet="|||0px|false|false" custom_margin_phone="" custom_margin_last_edited="on|desktop" custom_padding="60px||6px|||"][et_pb_column_inner saved_specialty_column_type="3_4" _builder_version="4.9.3" _module_preset="default"][et_pb_text _builder_version="4.9.3" _module_preset="default" min_height="34px" custom_margin="||4px|1px||"]
Related Samples
[/et_pb_text][et_pb_divider color="#E02B20" divider_weight="2px" _builder_version="4.9.3" _module_preset="default" width="10%" module_alignment="center" custom_margin="|||349px||"][/et_pb_divider][/et_pb_column_inner][/et_pb_row_inner][et_pb_row_inner use_custom_gutter="on" _builder_version="4.9.3" _module_preset="default" custom_margin="|||-44px||" custom_margin_tablet="|||0px|false|false" custom_margin_phone="" custom_margin_last_edited="on|tablet" custom_padding="13px||16px|0px|false|false"][et_pb_column_inner saved_specialty_column_type="3_4" _builder_version="4.9.3" _module_preset="default"][et_pb_blog fullwidth="off" post_type="project" posts_number="5" excerpt_length="26" show_more="on" show_pagination="off" _builder_version="4.9.3" _module_preset="default" header_font="|600|||||||" read_more_font="|600|||||||" read_more_text_color="#e02b20" width="100%" custom_padding="|||0px|false|false" border_radii="on|5px|5px|5px|5px" border_width_all="2px" box_shadow_style="preset1"][/et_pb_blog][/et_pb_column_inner][/et_pb_row_inner][/et_pb_column][et_pb_column type="1_4" _builder_version="3.25" custom_padding="|||" custom_padding__hover="|||"][et_pb_sidebar orientation="right" area="sidebar-1" _builder_version="4.9.3" _module_preset="default" custom_margin="|-3px||||"][/et_pb_sidebar][/et_pb_column][/et_pb_section]